154 patents
Page 5 of 8
Utility
Testing Method for a Dry Powder Inhaler
16 Sep 21
The invention provides a method of testing an inhaler based on performing an optical analysis of a dry powder medicament plume discharged from the inhaler upon actuation.
Denis Henry O'SULLIVAN, Daniel R BUCK
Filed: 2 Jun 21
Utility
Testing Method for a Dry Powder Inhaler
16 Sep 21
The invention provides a method of testing an inhaler based on performing an optical analysis of a dry powder medicament plume discharged from the inhaler upon actuation.
Denis Henry O'SULLIVAN, Daniel R. BUCK
Filed: 2 Jun 21
Utility
Inhaler
22 Jul 21
The introduction of electronics into a drug delivery device may introduce certain technical challenges, such as durability, electro-mechanical integration, and drug delivery performance.
Enrique Calderon Oliveras, Daniel Buck, Erica Jamie Kantor, Ross William Weir, James Roche, Steven David Gardner, Robert Owen Kivlin
Filed: 6 Apr 21
Utility
Solid state forms of ixazomib citrate
6 Jul 21
The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof.
Martin Valik, Roman Gabriel, Pavel Vraspir, David Lukas
Filed: 26 Feb 20
Utility
Solid State Forms of Branaplam and Their Preparation
17 Jun 21
Luna Ben-Sahel Katsav, Doron Rudik, Firas Masri, Motti Erlich, Polina Lapido, Ofir Shaul, Sigalit Patael
Filed: 5 Sep 19
Utility
Assistive Device for Use with a Syringe
10 Jun 21
An assistive device for use with a syringe comprises a housing for accommodating the syringe, a dispense member to be moved in a distal direction for dispensing a medicament from the syringe and a needle guard for covering a needle of the syringe before operation of the device.
Christopher Louis BELISLE, Daniel Casey JOHNSON
Filed: 14 Aug 19
Utility
Treating refractory migraine
8 Jun 21
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal, Ernesto Aycardi
Filed: 21 Oct 20
Utility
Treating refractory migraine
8 Jun 21
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal, Ernesto Aycardi
Filed: 21 Oct 20
Utility
Solid State Forms of Lorlatinib and Their Preparation
3 Jun 21
The present disclosure relates to Lorlatinib solid state forms, Lorlatinib salts and solid states thereof, processes for preparation thereof, pharmaceutical compositions and methods of use thereof.
Maja Matanovic Skugor, Ivica Grebenar, Nea Baus Topic, Dijana Skalec Samec, Edi Topic
Filed: 19 Apr 19
Utility
Improved Processes for the Preparation of Guadecitabine and Intermediates Thereof
20 May 21
Described are procedures and intermediates for the preparation of guadecitabine, and guadecitabine salts and solid state forms thereof.
Jana ROHACOVA, Jiri ZUREK, Hana KANTOR, Ales HUSEK
Filed: 11 Jul 18
Utility
Compliance Monitoring Module for a Breath-actuated Inhaler
13 May 21
A compliance monitoring module for a breath-actuated inhaler comprising: a miniature pressure sensor, a sensor port of said sensor being pneumatically coupled to a flow channel through which a user can inhale; a processor configured to: receive a signal originating from a dosing mechanism of the inhaler indicating that medication has been released; receive data from a sensing element of the sensor; and based on said signal from said dosing mechanism and said data from said sensing element, make a determination that inhalation of a breath containing medication through said flow channel complies with one or more predetermined requirements for successful dosing; and a transmitter configured to, responsive to said determination, issue a dosing report.
Mark Steven Morrison, Douglas E. Weitzel, Enrique Calderon Oliveras, Daniel Buck
Filed: 22 Jan 21
Utility
Inhaler
11 May 21
The introduction of electronics into a drug delivery device may introduce certain technical challenges, such as durability, electro-mechanical integration, and drug delivery performance.
Enrique Calderon Oliveras, Daniel Buck, Erica Jamie Kantor, Ross William Weir, James Roche, Steven David Gardner, Robert Owen Kivlin
Filed: 14 Sep 17
Utility
Compliance Monitoring Module for an Inhaler
6 May 21
A compliance monitoring module for an inhaler comprising: a miniature pressure sensor, a sensor port of said sensor being configured to be pneumatically coupled to a flow channel of said inhaler through which a user can inhale; a processor configured to: receive data from a sensing element of the pressure sensor; receive data from a mode sensor configured to detect when the inhaler changes from an inactive mode to an active mode; and based on said data from said pressure sensor sensing element and said data from said mode sensor, compile a compliance report; and a transmitter configured to issue said compliance report.
Mark Steven Morrison, Douglas E. Weitzel, Enrique Calderon Oliveras, Daniel Buck
Filed: 14 Jan 21
Utility
Salts and Solid State Forms of Plinabulin
29 Apr 21
Marisa Martinelli, Pavel Kolesa, Donato Motolese, Paolo Simone Tiseni
Filed: 1 Aug 18
Utility
Training in dispensing a medicament
6 Apr 21
A medicament-free device (e.g., a smartphone device) for simulating a medicament dispenser may include a sensing device and a processor.
Mark Milton-Edwards
Filed: 5 Jan 18
Utility
Position-specific Asymmetric Deuterium Enriched Catecholamine Derivatives and Medicaments Comprising Said Compounds
1 Apr 21
Rudolf-Giesbert ALKEN, Frank Schneider
Filed: 13 Aug 20
Utility
Aerosol device
30 Mar 21
The present invention provides an aerosol device for delivering a pharmaceutical formulation by inhalation via the mouth to the lungs or to the nostril in metered doses comprising: a pressurised aerosol canister including a vial containing a pharmaceutical formulation comprising an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further comprising a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a delivery outlet and a stem block, the stem block having a receptacle into which the valve stem of the metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice arranged to direct the pharmaceutical formulation through the delivery outlet, a transfer tunnel having an input opening and an output opening through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice, and a land length defining the distance from between the input opening and output opening, wherein the input opening and the output opening have cross-sectional areas of from 0.002 to 0.8 mm2 and the cross-sectional area of the input opening is smaller than the cross-sectional area of the output opening, and wherein the land length is from 0.5 mm to 10 mm.
James Noel Power, Simon Kaar, Andrew Gibbs
Filed: 13 May 15
Utility
Crystalline Siponimod Fumaric Acid and Polymorphs Thereof
25 Mar 21
Disclosed crystalline Siponimod fumaric acid, solid state forms (polymorphs) thereof, processes for preparation thereof and pharmaceutical compositions thereof.
Marisa MARTINELLI, Pavel KOLESA, Maurizio PAIOCCHI, Matteo TOSO, Roberta VOLONTÉ, Piero PARAVIDINO
Filed: 22 Jan 19
Utility
Processes for the preparation of Niraparib and intermediates thereof
23 Feb 21
The present invention relates to novel procedures and novel intermediates useful in the synthesis of Niraparib or any salt thereof.
Parven K. Luthra, Sanjay L. Vasoya, Bhatu T. Patil, Amit K. Taneja, Naveen C. Srivastav, Rinku Singh
Filed: 14 Aug 18
Utility
Sustained Release Olanzapine Formulations
18 Feb 21
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof.
Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
Filed: 11 May 20